Daniel P. Petrylak, MD, Reviews Ongoing Clinical Trials in Bladder Cancer

CancerNetwork® spoke with Daniel P. Petrylak, MD, professor of medicine (medical oncology) and of urology and co-leader of Cancer Signaling Networks at Yale Cancer Center, about ongoing clinical trials and treatment combinations in bladder cancer at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, hosted by Physicians’ Education Resource®, LLC, for which he served as meeting co-chair.

Transcript:

There are trials upfront looking at agents such as enfortumab [vedotin; Padcev] combined with pembrolizumab [Keytruda], and it’s being compared with the standard-of-care chemotherapy in both in the neoadjuvant [NCT04700124] as well as the metastatic setting [NCT04223856]. There are trials that are looking at other forms of maintenance therapy. There’s one that’s going to be done with cooperative groups looking at avelumab [Bavencio] combined with the cabozantinib [Cabometyx], which is a tyrosine kinase inhibitor that is approved as a single agent] for renal cancer at this point, and that’s going to be compared with avelumab alone.¹

There are a number of trials that are looking at immune therapy in various combinations. Right now, there’s a randomized phase 2 [trial] comparing enfortumab combined with pembrolizumab, and enfortumab alone in patients who have platinum-ineligible urothelial carcinoma that’s metastatic [NCT03288545].² There are a number of trials and all clinicians should consult clinicaltrials.gov to look for information.

References

1. FDA grants regular approval to cabometyx for first-line treatment of advanced renal cell carcinoma. News Release. FDA. December 19, 2017. Accessed March 21, 2022. https://bit.ly/3ipAzXk

2. Friedlander TW, Milowsky MI, Asim M, et al. Study EV-103: Update on durability results and long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC). J Clin Oncol. 2021; 39(suppl 15):4528. doi: 10.1200/JCO.2021.39.15_suppl.4528